LRLucas Rebiffé

Lucas Rebiffé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucas Rebiffé has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Filipe De Vadder

    Institut de Génomique Fonctionnelle de Lyon, Ecole Normale Supérieure de Lyon, CNRS UMR 5242, Université Claude Bernard Lyon 1

    4 shared publications
  • François Leulier

    Institut de Génomique Fonctionnelle de Lyon, Ecole Normale Supérieure de Lyon, CNRS UMR 5242, Université Claude Bernard Lyon 1

    4 shared publications
  • Amélie Joly

    Institut de Génomique Fonctionnelle de Lyon, Ecole Normale Supérieure de Lyon, CNRS UMR5242, Université Claude Bernard Lyon 1, Lyon, France

    3 shared publications
  • Estelle Caillon

    Institut de Génomique Fonctionnelle de Lyon, École Normale Supérieure de Lyon, CNRS UMR 5242, UCBL Lyon-1 Lyon F-69007

    2 shared publications
  • Julien Dellinger

    Institut de Génomique Fonctionnelle de Lyon, École Normale Supérieure de Lyon, CNRS UMR 5242, UCBL Lyon-1 Lyon F-69007

    2 shared publications
  • Yves Dusabyinema

    Institut de Génomique Fonctionnelle de Lyon, École Normale Supérieure de Lyon, CNRS UMR 5242, UCBL Lyon-1 Lyon F-69007

    2 shared publications

Latest Publications

  • Open Access

    OrganScaleR: An Open Shiny Tool for Principled Organ-Weight Inference in Mouse Physiology

    by Lucas Rebiffe, Laurent Gilquin, Francois Leulier, Filipe De Vadder

    Background: Organ weights are often divided by body weight to report "relative" organ size. Yet ratios usually stay size-dependent and become misleading. We built a simple decision path for size adjustment and wrapped it in a Shiny application so physiologists can get correct answers without coding. Methods: We reused liver and body-weight data from a mouse nutrition study for confirmatory examples in two common cases: when diet groups shared a wide body-size range, and when diet produced much smaller animals with little overlap. We compared liver-to-body-weight ratios with size-adjusted regression when the body-size overlap allowed comparisons, and with causal Bayesian mediation when it did not. The full workflow was implemented in OrganScaleR, a guided R Shiny application. Results: The ratio-normalized organ weight is still associated with body weight, leading to misleading comparisons. Modeling liver weight against body weight gave more cautious, size-adjusted effects when groups shared a common size range. When diets shifted body size strongly and overlap was limited, causal mediation showed that most organ differences followed the change in body weight rather than an organ-specific action. Simulations confirmed that ratios can generate false positives and biased estimates under allometric scaling, while model-based approaches remained reliable. OrganScaleR implements this decision workflow in a guided Shiny application that returns interpretable effects. Conclusions: OrganScaleR selects scale, enforces common support, and routes the analysis to size-adjusted ANCOVA or causal Bayesian mediation depending on body-weight overlap. It reports adjusted effects in original units through a point-and-click workflow, removing the statistical barrier to abandoning ratio normalization.


  • Open Access

    Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism

    by Amélie Joly, Lucas Rebiffé, Yves Dusabyinema, Julien Dellinger, Estelle Caillon, Karine Gauthier, François Leulier, Filipe De Vadder

    Animals rely on linear growth to attain their full adult size. The regulators of this multifactorial process, including environmental and endocrine cues, are still incompletely understood. Notably, GLP-1, glucagon-like peptide 1 (GLP-1) has emerged as a potential player in this process. Here, we employ semaglutide, a pharmaceutical GLP-1R agonist as a tool to mechanistically dissect the interplay between GLP-1 receptor activation, energy metabolism, and linear growth during the juvenile period, independent of its clinical applications. Using a juvenile mouse model, we show that chronic semaglutide treatment lowers blood glucose without affecting food intake or weight gain in juveniles with a normal growth pattern. However, in growth-stunted juveniles, semaglutide treatment exacerbates linear growth impairment through at least 2 concomitant mechanisms: a moderate reduction in food intake, and a decreased catabolic activity incompatible with tissue growth. These data suggest a complex interplay between GLP-1 signaling, energy metabolism, and growth during juvenile development. Overall, these findings highlight the value of semaglutide as a mechanistic tool for understanding how GLP-1 receptor activation modulates growth and metabolism in juveniles, emphasizing the importance of developmental context for interpreting its effects.


  • Open Access

    Liver FGF21 mediates sex-specific adaptation to juvenile protein malnutrition

    by Amélie Joly, Lucas Rebiffé, Anne Lambert, Estelle Caillon, Sandrine Hughes, Benjamin Gillet, Isabelle Rahioui, Pedro Da Silva, Justine Bruse, Anne Fougerat, et al.

    Dietary protein sufficiency during childhood is essential for healthy growth and tissue development. Chronic protein deficiency leads to stunting, height-for-age more than two standard deviations below the median, and affects 149 million children under five ( https://www.who.int/publications/i/item/9789240073791 ). Linear growth is governed by the somatotropic axis, wherein pituitary growth hormone (GH) stimulates hepatic insulin-like growth factor 1 (IGF-1) to promote bone elongation 1 . Although boys are consistently more stunted than girls across populations (ranging from 18% to 45%) 2,3 , mechanisms underlying this apparent resilience remain unclear. Rodent studies suggest that the protein-to-carbohydrate ratio modulates life-history traits such as metabolism, lifespan, and reproduction, with evidence of sex-dependent sensitivity 4,5 . Whether such dimorphism reflects coordinated developmental adaptations in response to protein scarcity, particularly in females, has not been fully explored. Here, we show that juvenile dietary protein restriction causes sexually dimorphic adaptations with pronounced stunting in males and delayed reproductive maturation in females. Using liver-specific deletion, we identify fibroblast growth factor 21 (FGF21) as a sex-specific hepatic regulator of female somatic growth and reproductive development, revealing a dimorphic endocrine adaptation to early-life protein scarcity. Our findings position FGF21 as a critical physiological checkpoint coordinating growth and reproductive timing in response to nutritional stress.


  • Open Access

    Semaglutide interferes with postnatal development of juvenile mice with compromised growth

    by Amélie Joly, Lucas Rebiffé, Yves Dusabyinema, Julien Dellinger, Karine Gauthier, François Leulier, Filipe De Vadder

    Objective Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to impact glucose homeostasis and, more recently, the somatotropic axis. While the effects of GLP-1RAs have been extensively studied in the context of diet-induced obesity, their impact on physiology in other nutritional contexts have been less explored. We investigated the potential beneficial effects of the GLP-1RA semaglutide during juvenile protein malnutrition, a dietary challenge known to cause stunted growth and to disrupt metabolic homeostasis. Methods We used a murine model to assess the effects of twice-weekly subcutaneous injections of semaglutide during juvenile protein malnutrition. Glucose metabolism was evaluated through in vivo oral glucose tolerance test, ex vivo glucose-stimulated insulin secretion in isolated pancreatic islets and histology of the pancreas. We combined linear growth monitoring, analysis of the growth hormone/insulin-like growth factor 1 signaling pathway and liver bulk RNA sequencing to characterize the effects of semaglutide on the somatotropic axis during juvenile protein malnutrition. Results Semaglutide improved glucose tolerance in control and malnourished mice, but differentially impacted pancreatic islet physiology depending on the dietary protein intake. While semaglutide did not alter growth in control conditions, it further inhibited growth of malnourished mice associated with reduction in fat but not lean mass. Surprisingly, semaglutide had no discernible effect on the functionality of the somatotropic axis in malnourished mice. Liver transcriptomics revealed that semaglutide may interfere with the growth of malnourished juvenile mice by altering circadian rhythm and thermogenesis. Conclusions Our data reveal that semaglutide interacts differentially with the physiology of juvenile mice depending on their dietary protein intake. We found that semaglutide influences glucose metabolism and linear growth in a diet-dependent manner, underscoring the importance of examining the effects of GLP-1RAs across various nutritional contexts and developmental stages. Highlights - Semaglutide hampers the growth of protein-malnourished, but not control-fed, juvenile animals. - The effects of semaglutide on linear growth are independent of alterations in the somatotropic axis. - Semaglutide differentially alters glucose metabolism of juvenile mice depending on their dietary protein intake.